UA118755C2 - Похідне дигідропіридазин-3,5-діону - Google Patents

Похідне дигідропіридазин-3,5-діону Download PDF

Info

Publication number
UA118755C2
UA118755C2 UAA201509770A UAA201509770A UA118755C2 UA 118755 C2 UA118755 C2 UA 118755C2 UA A201509770 A UAA201509770 A UA A201509770A UA A201509770 A UAA201509770 A UA A201509770A UA 118755 C2 UA118755 C2 UA 118755C2
Authority
UA
Ukraine
Prior art keywords
optionally substituted
methyl
alkyl
substituents
trifluoromethyl
Prior art date
Application number
UAA201509770A
Other languages
English (en)
Ukrainian (uk)
Inventor
Йосіхіто Охтаке
Наокі Окамото
Йосіюкі Оно
Хіротака Касівагі
Ацусі Кімбара
Такео ХАРАДА
Нобуюкі Хорі
Есіхіса Мурата
Кадзутака Татібана
Сота ТАНАКА
Кеніті Номура
Міцуакі Іде
Ейсаку Мідзугуті
Ясухіро Ітіда
Суіті Охтомо
Наосі Хоріба
Original Assignee
Чугаі Сейяку Кабусікі Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаі Сейяку Кабусікі Кайся filed Critical Чугаі Сейяку Кабусікі Кайся
Publication of UA118755C2 publication Critical patent/UA118755C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
UAA201509770A 2013-03-13 2014-03-13 Похідне дигідропіридазин-3,5-діону UA118755C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
JP2013132889 2013-06-25
PCT/JP2014/056778 WO2014142273A1 (ja) 2013-03-13 2014-03-13 ジヒドロピリダジン-3,5-ジオン誘導体

Publications (1)

Publication Number Publication Date
UA118755C2 true UA118755C2 (uk) 2019-03-11

Family

ID=51536921

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201509770A UA118755C2 (uk) 2013-03-13 2014-03-13 Похідне дигідропіридазин-3,5-діону

Country Status (29)

Country Link
EP (2) EP3757093A1 (enExample)
JP (2) JP5814488B2 (enExample)
KR (2) KR102072268B1 (enExample)
CN (1) CN105073715B (enExample)
AU (1) AU2014230552B2 (enExample)
BR (1) BR112015022092B1 (enExample)
CA (1) CA2901868C (enExample)
CL (1) CL2015002543A1 (enExample)
CR (1) CR20150505A (enExample)
DK (1) DK2975030T3 (enExample)
ES (1) ES2811126T3 (enExample)
HR (1) HRP20201211T1 (enExample)
HU (1) HUE050577T2 (enExample)
IL (1) IL240825B (enExample)
LT (1) LT2975030T (enExample)
MX (1) MX376532B (enExample)
MY (1) MY174269A (enExample)
NZ (1) NZ711182A (enExample)
PE (1) PE20151535A1 (enExample)
PH (1) PH12015501940A1 (enExample)
PL (1) PL2975030T3 (enExample)
PT (1) PT2975030T (enExample)
RS (1) RS60911B1 (enExample)
RU (1) RU2662832C2 (enExample)
SG (1) SG11201507345RA (enExample)
SI (1) SI2975030T1 (enExample)
TW (2) TWI683811B (enExample)
UA (1) UA118755C2 (enExample)
WO (1) WO2014142273A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014230552B2 (en) * 2013-03-13 2017-11-16 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative
EP4374877A3 (en) * 2014-09-12 2024-07-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification.
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110885290A (zh) * 2019-12-16 2020-03-17 阿里生物新材料(常州)有限公司 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法
CN115734965B (zh) 2020-06-26 2025-05-02 日本农药株式会社 芳基四氢哒嗪衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法
WO2022221182A1 (en) * 2021-04-12 2022-10-20 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc34a1 function
WO2022260064A1 (ja) 2021-06-08 2022-12-15 中外製薬株式会社 ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤
AR126060A1 (es) * 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
CA3244263A1 (en) 2021-12-28 2025-06-13 Nihon Nohyaku Co., Ltd. ARYL TETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, PESTICIDE CONTAINING SAID COMPOUND AND ASSOCIATED METHOD OF USE
WO2023219127A1 (ja) 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物
CN116217862A (zh) * 2023-03-21 2023-06-06 中国农业科学院农业环境与可持续发展研究所 一种可降解生物膜助剂的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100663147B1 (ko) * 2002-02-19 2007-02-28 오노 야꾸힝 고교 가부시키가이샤 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
TWI441637B (zh) * 2005-05-18 2014-06-21 Array Biopharma Inc Mek雜環抑制劑及其使用方法
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
UA97498C2 (ru) * 2006-11-03 2012-02-27 Басф Се Способ получения дифторметилпиразолилкарбоксилатов
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
CN102264740B (zh) * 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
MX2012012421A (es) * 2010-04-28 2012-12-17 Astellas Pharma Inc Compuestos tetrahidrobenzotiofena.
EP2590965B1 (en) * 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PL2772490T3 (pl) 2011-10-27 2016-11-30 Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
AU2014230552B2 (en) * 2013-03-13 2017-11-16 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative

Also Published As

Publication number Publication date
SI2975030T1 (sl) 2020-10-30
HUE050577T2 (hu) 2020-12-28
LT2975030T (lt) 2020-09-25
MY174269A (en) 2020-04-01
TW201446756A (zh) 2014-12-16
BR112015022092A8 (pt) 2018-01-23
HK1212700A1 (zh) 2016-06-17
CA2901868C (en) 2022-05-03
PE20151535A1 (es) 2015-10-28
JP6420738B2 (ja) 2018-11-07
JP2016040262A (ja) 2016-03-24
TW201741304A (zh) 2017-12-01
KR20160119282A (ko) 2016-10-12
BR112015022092B1 (pt) 2023-04-11
CR20150505A (es) 2015-10-26
IL240825B (en) 2020-07-30
EP2975030B1 (en) 2020-07-15
NZ711182A (en) 2020-05-29
DK2975030T3 (da) 2020-08-31
MX2015012537A (es) 2016-02-10
CN105073715B (zh) 2017-12-01
PH12015501940B1 (en) 2016-01-11
KR101664460B1 (ko) 2016-10-10
AU2014230552B2 (en) 2017-11-16
RS60911B1 (sr) 2020-11-30
MX376532B (es) 2025-03-07
PL2975030T3 (pl) 2021-01-11
EP2975030A4 (en) 2016-08-03
PT2975030T (pt) 2020-09-28
EP3757093A1 (en) 2020-12-30
KR20150127721A (ko) 2015-11-17
JPWO2014142273A1 (ja) 2017-02-16
ES2811126T3 (es) 2021-03-10
RU2662832C2 (ru) 2018-07-31
SG11201507345RA (en) 2015-10-29
TWI596095B (zh) 2017-08-21
AU2014230552A1 (en) 2015-08-13
WO2014142273A1 (ja) 2014-09-18
IL240825A0 (en) 2015-10-29
EP2975030A1 (en) 2016-01-20
CA2901868A1 (en) 2014-09-18
BR112015022092A2 (pt) 2017-07-18
PH12015501940A1 (en) 2016-01-11
CN105073715A (zh) 2015-11-18
JP5814488B2 (ja) 2015-11-17
CL2015002543A1 (es) 2016-02-26
TWI683811B (zh) 2020-02-01
HRP20201211T1 (hr) 2020-11-13
RU2015143507A (ru) 2017-04-19
KR102072268B1 (ko) 2020-01-31

Similar Documents

Publication Publication Date Title
CA2901868C (en) Dihydropyridazine-3,5-dione derivative
AU2017306605B2 (en) Nitrogen-containing tricyclic compounds and uses thereof in medicine
KR102336291B1 (ko) 암을 치료하기 위한 NIK 억제제로서의 3-(2-아미노피리미딘-4-일)-5-(3-하이드록시프로피닐)-1H-피롤로[2,3-c]피리딘 유도체
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
WO2022047031A1 (en) Inhibitors of apol1 and methods of using same
KR20220128345A (ko) 라파마이신 유사체 및 이의 용도
JP2025505644A (ja) Apol1の阻害剤としての4’,5’-ジヒドロスピロ[ピペリジン-4,7’-チエノ[2,3-c]ピラン]誘導体、及びそれを使用する方法
ES2975807T3 (es) Compuesto farmacéutico que contiene inhibidor del transportador de fosfato dependiente de sodio y adsorbente de fósforo para uso en la prevención, tratamiento o supresión de enfermedad renal crónica, arteriosclerosis asociada con calcificación vascular o calcificación ectópica
JP2023554643A (ja) Cdk阻害剤及び医薬としてのその使用
JP2023522863A (ja) Egfr阻害剤としての三環式化合物
US9499553B2 (en) Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
RU2811864C1 (ru) Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата
IL317345A (en) Tricyclic substances and pharmaceutical preparations containing them
EA050799B1 (ru) Гетероарильные гетероциклические соединения и их применение